Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma

NCT00113204 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: IPI-504

Sponsor

Infinity Pharmaceuticals, Inc.